The three families of monoclonal antibodies approved to treat rheumatoid arthritis are directed against IL-6, B lymphocyte surface protein CD20 and TNFα, three targets of potential interest for further investigation in COVID-19 treatment. Here, IL6 is linked to COVID-19.